Estrella Immunopharma annual shares outstanding
2021
2022
2022
2023
2024
2024
2025
Estrella Immunopharma Shares Outstanding History (ESLA)
Estrella Immunopharma reported 42.7M shares outstanding at the end of fiscal 2025.
View full Estrella Immunopharma company overviewEstrella Immunopharma annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 42.7M | 6.5M | +17.88% |
| 2024 · Dec 31 | 2024-12-31 | 36.2M | — | — |
| 2024 · Jun 30 | 2024-06-30 | 36.6M | 35.6M | +3642.51% |
| 2023 | 2023-06-30 | 978,243 | −34.2M | −97.22% |
| 2022 | 2022-12-31 | 1.4M | 0 | 0.00% |
| 2022 | 2022-06-30 | 35.2M | — | — |
| 2021 | 2021-12-31 | 1.4M | — | — |
Estrella Immunopharma quarterly shares outstanding
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 43.5M | 6.4M | +17.35% |
| Q1 2026 | 2026-03-31 | 43.0M | 6.9M | +18.99% |
| Q4 2025 | 2025-12-31 | 42.7M | 6.5M | +17.88% |
| Q3 2025 | 2025-09-30 | 37.8M | 1.6M | +4.38% |
| Q2 2025 | 2025-06-30 | 37.1M | 454,719 | +1.24% |
| Q1 2025 · Mar 31 | 2025-03-31 | 36.2M | −370,391 | −1.01% |
| Q4 2024 · Dec 31 | 2024-12-31 | 36.2M | 992,659 | +2.82% |
| Q1 2025 · Sep 30 | 2024-09-30 | 36.2M | 977,915 | +2.78% |
| Q4 2024 · Jun 30 | 2024-06-30 | 36.6M | 35.6M | +3642.51% |
| Q3 2024 | 2024-03-31 | 36.5M | — | — |
| Q2 2024 | 2023-12-31 | 35.2M | 33.8M | +2379.48% |
| Q1 2024 | 2023-09-30 | 35.2M | 33.8M | +2379.48% |
| Q4 2023 | 2023-06-30 | 978,243 | −441,457 | −31.10% |
| Q4 2022 | 2022-12-31 | 1.4M | 0 | 0.00% |
| Q3 2022 | 2022-09-30 | 1.4M | 0 | 0.00% |
| Q2 2022 | 2022-06-30 | 1.4M | — | — |
| Q1 2022 | 2022-03-31 | 1.4M | — | — |
| Q4 2021 | 2021-12-31 | 1.4M | — | — |
| Q3 2021 | 2021-09-30 | 1.4M | — | — |
Estrella Immunopharma Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. Estrella Immunopharma share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
Estrella Immunopharma used $29,462 to repurchase common stock in fy 2025. Across the latest 3 reported fiscal years, total share repurchases were $383,902. The latest reported quarter showed $0 of share repurchases.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2025 | 2025-12-31 | $29,462 |
| 2024 · Jun 30 | 2024-06-30 | $354,440 |
| 2023 | 2023-06-30 | $0 |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
Estrella Immunopharma shares outstanding trends
Between the periods ended 2021-12-31 and 2025-12-31, Estrella Immunopharma's shares outstanding moved from 1.4M to 42.7M, a change of 41.2M. The latest reported quarter, Q2 2026, shows 43.5M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Estrella Immunopharma source filings ↗